Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765804 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
A Phase 2 study of Dry Eye Syndrome, sponsored by Eyegate Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 2
- Study locations
NCT00765804 is a Phase 2 study of Dry Eye Syndrome that has completed, run by Eyegate Pharmaceuticals. The registered enrollment target is 89 participants, below the 156-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (43% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00765804, a Phase 2 study of Dry Eye Syndrome, has completed, sponsored by Eyegate Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with dry eye.
Conditions Studied
Interventions
- DRUG EGP-437 with EyeGate® II System
- DRUG Sodium citrate buffer solution with EyeGate® II System
Study Locations (2)
Massachusetts
- Ophthalmic Research Associates - Andover
- Ophthalmic Research Associates - North Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765804
The ClinicalTrials.gov registry entry for NCT00765804 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (43% lower). The listed sponsor is Eyegate Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Syndrome appearing as the primary indexed condition, and to 2 interventions - of which EGP-437 with EyeGate® II System is the first listed.
NCT00765804 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00765804 about?
NCT00765804 is a clinical study titled "Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye". The purpose of this study is to assess the safety and efficacy of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with dry eye.
What is the current status of trial NCT00765804?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2008-10. Estimated completion is 2009-02.
What conditions does trial NCT00765804 study?
This clinical trial studies the following conditions: Dry Eye Syndrome.
What interventions are being tested in trial NCT00765804?
The interventions under investigation include: EGP-437 with EyeGate® II System (DRUG), Sodium citrate buffer solution with EyeGate® II System (DRUG).
Who is sponsoring clinical trial NCT00765804?
This trial is sponsored by Eyegate Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00765804 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
COMPLETED · Phase 2
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
RECRUITING · Phase 1
-
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
COMPLETED · NA
-
Study of SkQ1 as Treatment for Dry-eye Syndrome
COMPLETED · Phase 3
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
COMPLETED · Phase 1
-
Effects of Dry Eye Treatments on the Ocular Surface
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.